Maxim Group analyst Jason McCarthy maintained a Buy rating on Entera Bio Ltd (ENTX) today and set a price target of $12. The company’s shares opened today at $4.02.
McCarthy observed:
“Entera Bio reported YE18 results with a net loss of ($10.3M) and ended the year with $11.5M in cash on the balance sheet.”
According to TipRanks.com, McCarthy has 0 stars on 0-5 star ranking scale with an average return of -6.5% and a 30.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Adial Pharmaceuticals Inc.
Currently, the analyst consensus on Entera Bio Ltd is a Moderate Buy with an average price target of $12.
See today’s analyst top recommended stocks >>
Based on Entera Bio Ltd’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $1.56 million. In comparison, last year the company had a GAAP net loss of $3.78 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. It develops an oral formulation of parathyroid hormone. The company was founded on June 1, 2010 and is headquartered in Jerusalem, Israel.
